Breakthrough In Two Pages: FDA Offers Preliminary Advice
This article was originally published in The Pink Sheet Daily
Agency now allows sponsors of potential breakthrough therapies to request preliminary advice, but sponsors may not necessarily want to use it.
You may also be interested in...
Breakthrough Denial Doesn't Mean US FDA Won't Bring Full Resources To Application
Agency staff discuss how they offer early development advice to sponsors before a breakthrough decision is made and reassure them if the status is denied.
FDA's Breakthrough Workload Will Be Eased By Hiring Reviewers With PDUFA VI Funds
User fees won't support dedicated staff, but rather FTEs that will work on the popular program as needed.
FDA's Breakthrough Bar May Be Set Too Low, Jenkins Says
Office of New Drugs Director recommends that EMA be careful how its sets the bar for its similar PRIME program to ensure it remains meaningful.